Apparent decrease in population clearance of theophylline: Implications for dosage

被引:3
作者
Asmus, MJ
Weinberger, MM
Milavetz, G
Marshik, P
Teresi, ME
Hendeles, L
机构
[1] UNIV IOWA HOSP & CLIN, DEPT PEDIAT, DIV CLIN & ADM PHARM, COLL PHARM, IOWA CITY, IA 52242 USA
[2] UNIV IOWA HOSP & CLIN, PEDIAT ALLERGY & PULM DIV, COLL MED, IOWA CITY, IA 52242 USA
[3] UNIV FLORIDA, COLL PHARM, DEPT PHARM PRACTICE, GAINESVILLE, FL USA
[4] UNIV FLORIDA, COLL MED, PEDIAT PULM DIV, GAINESVILLE, FL USA
关键词
D O I
10.1016/S0009-9236(97)90043-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Having observed in recent years that the theophylline dose requirements needed to attain peak serum concentrations of 10 to 20 mu g/ml infrequently reached previously described mean values, we hypothesized that a downward shift in the range of dose requirements had occurred among patients with asthma. Study design: We examined dosage requirements needed to attain peak serum concentrations of 10 to 20 mu g/ml in all patients with chronic asthma treated with theophylline by the Pediatric Allergy and Pulmonary Clinic at the University of Iowa from 1990 to 1994 (n = 300) and at the Pediatric Pulmonary Clinic at the University of Florida from 1992 to 1995 (n = 93), We then compared these doses to previous dose requirements from 1978 to 1983 determined in the same manner. Results: Despite similar mean peak serum concentrations during both time periods (14 mu g/ml), mean theophylline dosage requirements during the period of this study were approximately 25% lower among all age groups than those previously observed (p < 0.001), There were no significant differences in mean dosage requirements between the Iowa and Florida patients in any age group examined. Conclusions: Theophylline dose requirements needed to attain serum concentrations of 10 to 20 mu g/ml have decreased significantly from those on which current dosing recommendations are based, This suggests a decrease in mean clearance of the population.
引用
收藏
页码:483 / 489
页数:7
相关论文
共 46 条
[1]   THEOPHYLLINE PHARMACOKINETICS IN ADVANCED AGE [J].
ANTAL, EJ ;
KRAMER, PA ;
MERCIK, SA ;
CHAPRON, DJ ;
LAWSON, JR .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 12 (05) :637-645
[2]  
Cabanas R, 1982, An Esp Pediatr, V16, P119
[3]  
Cabanas R, 1981, An Esp Pediatr, V14, P89
[4]  
CHANG KC, 1978, LANCET, V1, P1132
[5]  
CLARK CJ, 1979, LANCET, V1, P492
[6]   THEOPHYLLINE KINETICS IN RELATION TO AGE - THE IMPORTANCE OF SMOKING [J].
CUSACK, B ;
KELLY, JG ;
LAVAN, J ;
NOEL, J ;
OMALLEY, K .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 10 (02) :109-114
[7]  
ELLIS EF, 1976, PEDIATRICS, V58, P542
[8]  
FELDMAN CH, 1980, PEDIATRICS, V66, P956
[9]   EFFECT OF PREDNISOLONE ON THEOPHYLLINE PHARMACOKINETICS IN PATIENTS WITH CHRONIC AIR-FLOW OBSTRUCTION [J].
FERGUSSON, RJ ;
SCOTT, CM ;
RAFFERTY, P ;
GADDIE, J .
THORAX, 1987, 42 (03) :195-198
[10]  
FLEETHAM JA, 1978, LANCET, V2, P898